Podcast episode 110 (in German)
Sleep apnea – the tube that solves the problem but not the heart attack
October 18, 2026
A breathing mask lowers breathing pauses during sleep from 29 to 3.7 per hour — and in the largest trial on the subject it changes nothing about heart attacks and strokes. This episode shows what the device is good for nonetheless and why nobody should put it aside because of this.
What it is about
In sleep apnea, the throat repeatedly collapses during sleep, oxygen drops, and the brain briefly wakes up. That those affected have more cardiovascular events is well established as an association. The episode examines whether treatment with a positive pressure mask resolves this association — in exactly the group that would have the most to gain. The result is split in two: for the heart there is no benefit, for snoring, daytime sleepiness, quality of life and mood there very much is. After that it turns to routine care data that look quite different, and to a newly approved drug that was again measured only by the breathing index. The conclusion: the device is built for the night, not against the heart attack.
Key points
- In the large randomized trial with 2,717 adults aged 45 to 75, all with a heart or vascular disease, the breathing index fell from 29 to 3.7 with the mask.
- After an average of 3.7 years, 229 treated participants had an event, 17 percent, versus 207 without a mask, 15.4 percent — hazard ratio 1.1, confidence interval 0.91 to 1.32.
- In the same trial, 4 out of 4 everyday measures improved meaningfully: snoring, daytime sleepiness, quality of life and mood.
- The device was used for an average of 3.3 hours per night, despite appointments and support — so the trial measures real-world use, not a full night.
- Routine care data from 34,782 insured people in California show a hazard ratio of 0.46 from 4 hours of use upwards, but almost the same, 0.53, below 4 hours.
- A review of 38 studies finds for mortality only 0.89 in the 16 randomized ones, confidence interval 0.66 to 1.21; only with observational data does this become 0.57.
- Since December 2024, tirzepatide has been approved in the US for moderate to severe sleep apnea in obesity; after 52 weeks the index was 20 and 23.8 events per hour lower than on placebo.
Where the data stop
The large mask trial was open-label: those who had the device knew it. For snoring and mood that is a real limitation, for heart attacks hardly. What remains open, however, is what a full night with the mask would achieve — the trial answers the everyday question with 3.3 hours, not the question about 8 hours. The favorable routine care data do not help here: if little use looks almost as good as enough, the figure measures the person who connects a device every evening rather than the device. The authors of the review themselves rate the strength of the evidence as low.
For the drug, too, the cardiac endpoint is unresolved, because both trials primarily measured the breathing index, at baseline values of 51.5 and 49.5. A tablet program with 712 randomized participants is ongoing; its design has been published, a result was not yet available at the time of the episode. Anyone who has been prescribed a device discusses stopping it where it was prescribed.
Listen (in German)
Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music
Published on October 18, 2026.
The topic in the database
- The breathing mask almost completely eliminates nighttime breathing pauses – but in the largest trial it did not thereby prevent heart attacks and …CPAP for sleep apnea
All episodes in the app (German)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-09-22.